CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor ConferenceLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 29, 2025 / Today, eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the Spartan Capital Securities Investor Conference on November 3, 2025, at the Marriott Marquis Hotel in New York City. Participation by eXoZymes underscores the conference's mission to spotlight innovative companies and emerging market leaders positioned for long-term growth.
CEO of eXoZymes to Present at ThinkEquity's Annual Investor ConferenceLOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the 2025 ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York City.
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical CommitteesLOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Today, eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that two of its senior leaders - CCO Damien Perriman and VP of Development, Dr. Paul Opgenorth - have been elected to key roles within the BioMADE Governance Committees.
eXoZymes Provides Second Quarter 2025 Update at 5PM EST TodayManagement to host earnings call at 5:00PM Eastern Time, today.
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM ESTLOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025.
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% PurityUsing eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.
eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 MonthsN-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free BiomanufacturingMONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2 million USD National Science Foundation (NSF) funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications.
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything PodcastMONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (
NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - was featured on the latest episode of the Grow Everything podcast, revealing how the company's AI-engineered exozymes are reshaping the next generation of biomanufacturing by enabling sustainable chemical production outside of living cells.
eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM ESTMONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (
NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx.
eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver HealthN-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantMonrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (
NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created.
eXoZymes Provides Fourth Quarter and Full Year 2024 UpdateManagement to Host Conference Call Today at 4:30PM Eastern
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (
NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call.
